Document Detail

Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
MedLine Citation:
PMID:  17524889     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Following renal transplantation, serum erythropoietin (EPO) levels gradually increase during the first 2 to 3 months. However, some transplant recipients continue to remain anemic. The aim of the present study was to correlate serum EPO concentrations with hematocrit (Hct) and hemoglobin (Hb) levels in hemodialysis (HD) patients and renal allograft recipients. METHODS: In a comparative cross-sectional study, serum EPO concentrations and Hb and Hct levels were measured in 35 chronic HD patients and 40 transplant recipients who had stable kidney function for at least 6 months after transplantation (group 1). The HD patients were further divided based on their recombinant human (rHu) EPO supplementation into those who received rHu EPO during dialysis (group 2A, n=15) and those who were not on rHu EPO (group 2B, n=20). Data are presented as mean values +/- SD. The statistical analysis was performed by SPSS version 11.0 using chi-square, ANOVA, and Pearson correlation tests. A general linear model (GLM) was used to compensate for the effects of age. The P value for significance was set at .05. RESULTS: Group 2B patients tended to be older than groups 1 and 2A (P=.014). The sex ratios were comparable among groups. Mean EPO level was 17.09 +/- 10.99 mIU/mL in recipients, which was comparable with that of HD patients (18.54 +/- 26.18 mIU/mL; P>.05). No significant correlation was observed between the serum EPO concentrations and Hb and Hct levels in recipients (P>.05). When comparing the 3 groups, EPO was not correlated with Hct and Hb in any group. Hb and Hct were significantly higher among HD patients not on rHu EPO therapy (P=.02). GLM, with age as a covariate, did not yield a significant difference between EPO levels of the studied groups (P=.36). CONCLUSIONS: This study showed that serum EPO level was in the normal range in recipients and HD patients. We were not able to find any correlation between Hb and Hct levels and EPO concentrations in any group of patients irrespective of rHu EPO supplementation. Hence, impaired EPO stimulatory effects may be considered a potential contributor to anemia in these patients.
H T Khosroshahi; M M Shoja; R S Tubbs; R Estakhri; M R Ardalan
Related Documents :
19870019 - Iv. hemoglobin injections and conservation of pigment by kidney, liver and spleen : the...
3108839 - Mitomycin c associated hemolytic uremic syndrome.
1180129 - Antazoline-induced immune hemolytic anemia, hemoglobinuria, and acute renal failure.
15877809 - Anti-cd20 monoclonal antibody (rituximab) for life-threatening hemolytic-uremic syndrome.
1415379 - Erythropoietin resistance due to vitamin b12 deficiency. case report and retrospective ...
7628289 - Non-hla-linked hemochromatosis in a chinese woman.
22228349 - Evolution of a ureteric stone from the renal pelvis to the ureter on skeletal scintigra...
18266799 - Kidney transplantation in children with posterior urethral valves.
25295579 - Light chain crystalline kidney disease: diagnostic urine microscopy as the "liquid kidn...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transplantation proceedings     Volume:  39     ISSN:  0041-1345     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-05-25     Completed Date:  2007-10-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1051-3     Citation Subset:  IM    
Department of Nephrology, Tabriz Medical University, Tabriz, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross-Sectional Studies
Erythropoiesis / physiology*
Erythropoietin / blood*,  therapeutic use
Kidney Failure, Chronic / surgery,  therapy
Kidney Transplantation / physiology*
Middle Aged
Recombinant Proteins / therapeutic use
Renal Dialysis*
Transplantation, Homologous / physiology
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Medical comorbidities after renal transplantation.
Next Document:  The outcome of diverticulosis in kidney recipients with polycystic kidney disease.